Season 10 · Episode 13
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
OncLive® On Air · OncLive® On Air
February 12, 20249m 6s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key efficacy and safety data from the EV-302 trial, and future directions in urothelial cancer research.